ClinicalTrials.gg
CompletedNCT06011200Updated Jul 3, 2025

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

A Phase 3 interventional study of MCV4 and MSPV4 in Epidemic Meningitis, sponsored by CanSino Biologics Inc.. Completed at 1 site in China. Open to participants aged 4 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by CanSino Biologics Inc. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
4 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.

Enrollment
8th of 19
1,000 · median 840
Started
2023
with 1 other
Phase 3
10 of 19
3 open now
Registered
10th of 19
by date
Lead sponsor
6 of 19
CanSino Biologics Inc.

Among the 19 studies in Meningitis, Meningococcal with a site in China, this one is the 8th largest by enrollment, is one of 2 that started in 2023, is one of 10 in phase 3, and was the 10th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 4 Years to 6 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Meningitis, Meningococcal with a site in China, or all of them as a file.
02

Study summary

The scientific name of meningococcus is Neisseria meningitidis (Nm), the causative agent of epidemic meningococcal meningitis (rheumatoid encephalitis), which colonizes the mucous membranes of the human nasopharynx or causes local infection and can cross the mucosal barrier to cause invasive bacteremia or epidemic meningococcal meningitis, meningococcus can often cause serious disease epidemics worldwide, the main clinical features of its infection are fever, rash and meningitis, the most common clinical manifestation is acute bacterial meningitis.

Read the detailed description

The preventive measures for influenza are based on strengthening personal protection, vaccination, strengthening surveillance, early detection of patients, and active isolation and treatment. The immune response to meningococcal polysaccharide vaccine is weak in infants under 2 years of age, and only a transient immune response is produced. Numerous experiments have shown that the immunogenicity of polysaccharides is enhanced by binding to protein carriers, and a significant booster effect is produced. Meningococcal polysaccharide conjugate vaccine induces a good immune response in infants and children under 2 years of age and produces immune memory, which enhances the immune effect of the vaccine and can eliminate the carrier state of infected patients.

03

Conditions studied

  • Epidemic Meningitis

Keywords

  • ACYW135
  • CRM197
  • Immunogenicity
  • Safety
  • 4~6 yearsof age
04

Who can participate

Ages eligible
4 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 4\~6 years old
  • Complete at least two doses of basic immunization with polysaccharide influenza vaccine according to the immunization program
  • The legal guardian or delegate has given , voluntarily signed the informed consent form, and is able to comply with the requirements of the clinical study protocol

Exclusion criteria

Exclusion Criteria:

  • Fever before inoculation, axillary temperature >37.0℃
  • Previous history of immunization with meningococcal polysaccharide conjugate vaccine
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
  • History of epilepsy, convulsions or seizures or a history of psychiatric illness or family history
  • Volunteers with current meningitis or a history of meningitis
  • Volunteers treated with therapy, cytotoxic therapy, (excluding topical treatment, surface treatment for acute uncomplicated dermatitis, spray treatment for allergic rhinitis) within the past 6 months (\<6 months)
  • Received blood/plasma products or immunoglobulins within 60 days (\<60 days) prior to study vaccination or planned to receive blood/plasma products or immunoglobulins throughout the study period
  • Suffering from serious chronic diseases or conditions that are in a progressive stage and cannot be controlled smoothly, such as thyroid disease
  • Volunteers with known or suspected diseases that are judged by the investigator to affect vaccination such as severe respiratory disease, acute infection or active chronic disease, severe cardiovascular disease, severe liver or kidney disease, , severe infectious or allergic skin disease
  • History of serious adverse reactions associated with the vaccine and/or history of severe allergic reactions (e.g., systemic allergic reactions) to any component of the vaccine
  • Immunocompromised individuals with known or suspected immunodeficiency as determined by medical history and/or physical examination (e.g., malignancy, , etc.)
  • Bleeding constitution or condition associated with prolonged bleeding, investigators consider intramuscular injection to be
  • given within 14 days, other vaccines given within 7 days
  • Participation in other studies involving interventions within 28 days (\<28 days) prior to study entry and/or during study participation
  • Other conditions judged by the investigator to be inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,000 participants (actual)

Study arms

  • Experimental
    ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)

    Intramuscular injection, 0.5ml

    Biological: MCV4

  • Active comparator
    ACYW135 Group Meningococcal Polysaccharide Vaccine (MSPV4)

    Subcutaneous injection, 0.5ml

    Biological: MSPV4

Interventions

  • BiologicalMCV4

    1 dose of MCV4 on Day 0

  • BiologicalMSPV4

    1 dose of MSPV4 on Day 0

06

What researchers measure

Primary outcomes

  1. Geometric mean titers (GMT) of meningococcal antibodies to groups A, C, Y and W135 in all subjects 30 days after immunization

    Time frame: 30 days after immunization

  2. Positive conversion rates of meningococcal antibodies to groups A, C, Y and W135 in all subjects 30 days after immunization

    Time frame: 30 days after immunization

  3. Incidence of adverse reactions within 30 minutes after immunization in all subjects

    Time frame: Within 30 minutes after immunization

  4. Incidence of adverse reactions/events within 7 days of immunization for all subjects

    Time frame: Within 7 days after immunization

  5. Incidence of adverse reactions/events within 30 days of exemption for all subjects

    Time frame: Within 30 days of exemption

Secondary outcomes

  1. Meningococcal positivity for groups A, C, Y, and W135 for all subjects 30 days after immunization

    Time frame: 30 days after immunization

  2. Geometric mean growth multiplier (GMI) for all subjects 30 days after immunization

    Time frame: 30 days after immunization

  3. Antibody titers ≥1:128 ratio for all subjects 30 days after immunization

    Time frame: 30 days after immunization

  4. Meningococcal antibody positivity for groups A, C, Y and W135 at 90 and 180 days of exemption in 500 subjects

    Time frame: 90 and 180 days of exemption

  5. GMT for groups A, C, Y and W135 at 90 and 180 days of exemption in 500 subjects

    Time frame: 90 and 180 days of exemption

  6. GMI for groups A, C, Y and W135 at 90 and 180 days of exemption in 500 subjects

    Time frame: 90 and 180 days of exemption

  7. Antibody titers ≥1:128 ratio for groups A, C, Y and W135 at 90 and 180 days of exemption in 500 subjects

    Time frame: 90 and 180 days of exemption

  8. Incidence of serious adverse events (SAEs) within 180 days of exemption in all subjects

    Time frame: Within 180 days of exemption

  9. All subjects were stratified into susceptible (<1:8) and non-susceptible (≥1:8) populations according to the 1:8 pre-immune antibody titer threshold

    Time frame: 30 days after immunization

07

Study locations

1 site
  • Shanyang County Center for Disease Prevention and Control
    Shanyang, Shaanxi, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2023, 2 months.

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Aug 25, 2023
StartActual
Sep 16, 2023
Primary completionActual
Dec 11, 2023
CompletionActual
May 11, 2024
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06011200
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Sep 16, 2023
Primary completion
Dec 11, 2023
Completion
May 11, 2024
Last update
Jul 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion